YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. The company is headquartered in Taipei City, Taipei. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
YDES stock price ended at $5.29 on 木曜日, after rising 1.93%
On the latest trading day May 07, 2026, the stock price of YDES rose by 1.93%, climbing from $5.19 to $5.29. Throughout the session, the stock experienced a volatility of 3.52%, with prices fluctuating between a daily low of $5.11 and a high of $5.29. Alongside this price increase, trading volume also rose by 1.7K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.1K shares were traded, amounting to a market value of approximately $373.0M.